Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 4/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23696647 | 0.85 | ALDH1A1 (0.59) | NPC1TP53ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL23945808 | 0.85 | SIGMAR1 (0.46) | NPC1TP53ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL23806983 | 0.83 | SMN1; SMN2 (0.46) | NPC1TP53ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL23946040 | 0.81 | ALDH1A1 (0.40) | NPC1TP53ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL25468604 | 0.80 | HTR1A (0.42) | HRH3SIGMAR1 | |
| SCHEMBL22799479 | 0.79 | NCF1 (0.49) | ALDH1A1KDM4EPOLBPKMHRH3 | |
| SCHEMBL20034212 | 0.79 | SIGMAR1 (0.68) | ALDH1A1SMN1; SMN2POLBPKMSIGMAR1 | |
| SCHEMBL24673562 | 0.78 | ALDH1A1 (0.41) | NPC1TP53ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL1126489 | 0.78 | SIGMAR1 (0.69) | KDM4EMEN1KMT2APOLBSIGMAR1 | |
| SCHEMBL24800866 | 0.77 | ALDH1A1 (0.47) | ALDH1A1KDM4EMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| WO-2023081759-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | NPC1 3159/4885TP53 1474/4885ALDH1A1 2776/4885 |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | NPC1 4456/4885TP53 2659/4885ALDH1A1 2904/4885 |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | NPC1 4139/4885TP53 2/4885ALDH1A1 1804/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | NPC1 4098/4885TP53 350/4885ALDH1A1 2230/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | NPC1 3159/4885TP53 1474/4885ALDH1A1 2776/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | NPC1 3159/4885TP53 1474/4885ALDH1A1 2776/4885 |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | NPC1 3159/4885TP53 1474/4885ALDH1A1 2776/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | NPC1 3159/4885TP53 1474/4885ALDH1A1 2776/4885 |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | NPC1 4506/4885TP53 76/4885ALDH1A1 3701/4885 |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | NPC1 3895/4885TP53 508/4885ALDH1A1 1538/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | NPC1 3159/4885TP53 1474/4885ALDH1A1 2776/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | NPC1 3159/4885TP53 1474/4885ALDH1A1 2776/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | NPC1 4386/4885TP53 612/4885ALDH1A1 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.